Clinical Studies on Traction Therapy
Outcomes of RestoreX Penile Traction Therapy in Men With Peyronie's Disease: Results From Open Label and Follow-up Phases
Conclusions: Penile Traction Therapy (PTT) with RestoreX results in significant improvements in length, curve, and subjective and objective measures of sexual function without significant adverse events. RestoreX PTT represents a safe, conservative, low-cost option for managing men with Peyronie’s Disease.
Efficacy of RestoreX after prostatectomy: open-label phase of a randomized controlled trial
Conclusions: In conclusion, this study supports earlier findings that the use of RxPTT beginning at 1 month post-prostatectomy improves penile length and helps preserve erectile function. Although limited, the crossover data suggest persistent improvements after treatment discontinuation, which, if confirmed, would represent the first therapy ever shown to preserve erectile function outside of nerve-sparing techniques. Based on limited data, men who initiated therapy in a delayed manner (i.e., at 6 months) did not experience similar benefits to those who began treatment earlier. External validation in a larger, multicentre series is currently ongoing.
A randomized, controlled clinical trial using the RestoreX device in men with Peyronie’s disease was completed at Mayo Clinic. Clinical results were published in The Journal of Urology in September 2019.
Conclusions: In summary, RestoreX is the only penile traction therapy device shown in a randomized controlled clinical trial to improve penile length and curvature in either 1, 2 or 3 30-minute treatment sessions per day for 12 weeks. Other traction products required up to 8 hours of daily use. In addition, men who used RestoreX experience improvements in erectile function, overall, compared to those in the control group. Finally, the results of the clinical trial demonstrated safety with only mild, temporary side effects with use.
A modern review of penile traction monotherapy and combination therapy for the treatment of peyronie’s disease
Conclusions: PTT appears to be a safe and well-tolerated treatment for PD as monotherapy or in combination with other nonsurgical and surgical treatments, and for men in both the acute and chronic phases. Further studies are needed to compare available devices, evaluate device characteristics associated with treatment success, differentiate outcomes in acute vs. chronic PD populations, and determine the optimal duration of use.
Penile Traction Therapy and Vacuum Erection Devices in Peyronie's Disease
Conclusions: PTT and VED represent viable therapeutic options for managing PD, with more data currently available on PTT. Because all PTT studies used a similar style of traction device, it is unclear whether results reflect outcomes of these particular devices or traction more broadly. Further studies are required to better delineate the benefits of PTT and VED, particularly in relation to other established treatments.
Emerging Roles of Penile Traction Therapy and Vacuum Erectile Devices
Conclusions: PTT and VED have been utilized in urologic and sexual conditions with various success. Several promising areas utilizing both PTT and VED are being studied, however, more research needs to be done in these areas prior to becoming a standard treatment. Mehr J, Santarelli S, Green TP, et al. Emerging Roles of Penile Traction Therapy and Vacuum Erectile Devices.
Applying extender devices in patients with penile dysmorphophobia: assessment of tolerability, efficacy, and impact on erectile function
Conclusions: Penile extender as a minimally invasive technique is safe and provides modest benefits and patient satisfaction.